SG10202108973SA - Improved serum albumin binders - Google Patents
Improved serum albumin bindersInfo
- Publication number
- SG10202108973SA SG10202108973SA SG10202108973SA SG10202108973SA SG10202108973SA SG 10202108973S A SG10202108973S A SG 10202108973SA SG 10202108973S A SG10202108973S A SG 10202108973SA SG 10202108973S A SG10202108973S A SG 10202108973SA SG 10202108973S A SG10202108973S A SG 10202108973SA
- Authority
- SG
- Singapore
- Prior art keywords
- serum albumin
- improved serum
- albumin binders
- binders
- improved
- Prior art date
Links
- 102000007562 Serum Albumin Human genes 0.000 title 1
- 108010071390 Serum Albumin Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/626—Diabody or triabody
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762446992P | 2017-01-17 | 2017-01-17 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10202108973SA true SG10202108973SA (en) | 2021-09-29 |
Family
ID=61163666
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10202108973SA SG10202108973SA (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
| SG11201906341XA SG11201906341XA (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201906341XA SG11201906341XA (en) | 2017-01-17 | 2018-01-17 | Improved serum albumin binders |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11897944B2 (en) |
| EP (1) | EP3571224A1 (en) |
| JP (2) | JP7300385B2 (en) |
| KR (2) | KR20230165374A (en) |
| CN (2) | CN117327175A (en) |
| AU (1) | AU2018209150A1 (en) |
| BR (1) | BR112019014600A2 (en) |
| CA (1) | CA3050574A1 (en) |
| IL (2) | IL305912A (en) |
| MX (1) | MX2019008536A (en) |
| SG (2) | SG10202108973SA (en) |
| WO (1) | WO2018134234A1 (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201805288QA (en) | 2014-05-16 | 2018-07-30 | Ablynx Nv | Improved immunoglobulin variable domains |
| US11414480B2 (en) * | 2016-12-07 | 2022-08-16 | Ablynx N.V. | Serum albumin binding immunoglobulin single variable domains |
| SG11201906264YA (en) * | 2017-01-17 | 2019-08-27 | Ablynx Nv | Improved serum albumin binders |
| BR112022010231A2 (en) | 2019-12-06 | 2022-09-06 | Ablynx Nv | POLYPEPTIDES COMPRISING SINGLE VARIABLE DOMAINS OF IMMUNOGLOBULIN TARGETED TNFALFA AND OX40L |
| CA3163877A1 (en) | 2019-12-06 | 2021-06-10 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting tnf.alpha. and il-23 |
| JP2023504914A (en) | 2019-12-09 | 2023-02-07 | アブリンクス・エヌ・フェー | Polypeptides containing immunoglobulin single variable domains that target IL-13 and TSLP |
| IL296767A (en) | 2020-03-30 | 2022-11-01 | Ablynx Nv | Method for the production and purification of multivalent immunoglobulin single variable domains |
| JP2023544124A (en) | 2020-09-25 | 2023-10-20 | アブリンクス エン．ヴェー． | Polypeptides containing immunoglobulin single variable domains that target IL-13 and OX40L |
| EP4237438A1 (en) | 2020-10-27 | 2023-09-06 | Beijing QL Biopharmaceutical Co., Ltd. | Fusion proteins of gdf15 and use thereof |
| CA3203141A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| WO2022129572A1 (en) | 2020-12-18 | 2022-06-23 | Ablynx Nv | Polypeptides comprising immunoglobulin single variable domains targeting il-6 and tnf-alpha |
| IL303783A (en) | 2020-12-18 | 2023-08-01 | Sanofi Sa | Polypeptides comprising immunoglobulin single variable domains targeting glypican-3 and t cell receptor |
| WO2023111266A1 (en) | 2021-12-17 | 2023-06-22 | Ablynx Nv | POLYPEPTIDES COMPRISING IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS TARGETING TCRαβ, CD33 AND CD123 |
| WO2023230488A1 (en) * | 2022-05-23 | 2023-11-30 | Cereius, Inc. | Her2-binding agents and uses thereof |
| US20240109965A1 (en) | 2022-06-14 | 2024-04-04 | Ablynx N.V. | Immunoglobulin single variable domains targeting t cell receptor |
| US20240132624A1 (en) | 2022-07-27 | 2024-04-25 | Ablynx N.V. | Polypeptides binding to a specific epitope of the neonatal fc receptor |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0739981A1 (en) | 1995-04-25 | 1996-10-30 | Vrije Universiteit Brussel | Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes |
| DK1027439T3 (en) | 1997-10-27 | 2010-05-10 | Bac Ip Bv | Multivalent antigen-binding proteins |
| US6742038B2 (en) | 2000-04-07 | 2004-05-25 | Danger, Inc. | System and method of linking user identification to a subscriber identification module |
| JP2005289809A (en) | 2001-10-24 | 2005-10-20 | Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) | Mutant heavy-chain antibody |
| CN1678634A (en) | 2002-06-28 | 2005-10-05 | 多曼蒂斯有限公司 | Immunoglobulin single variable antigen combination area and its opposite constituent |
| US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
| US20060002935A1 (en) | 2002-06-28 | 2006-01-05 | Domantis Limited | Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor |
| NZ540196A (en) | 2002-11-08 | 2008-09-26 | Ablynx Nv | Camelidae antibodies against imminoglobulin E and use thereof for the treatment of allergic disorders |
| KR20050092029A (en) | 2003-01-10 | 2005-09-16 | 아블린쓰 엔.브이. | Recombinant vhh single domain antibody from camelidae against von willebrand factor (vwf) or against collagen |
| WO2006059108A2 (en) | 2004-12-02 | 2006-06-08 | Domantis Limited | ANTI-IL-IRl SINGLE DOMAIN ANTIBODIES AND THERAPEUTIC USES |
| US8188223B2 (en) | 2005-05-18 | 2012-05-29 | Ablynx N.V. | Serum albumin binding proteins |
| PT2444424T (en) | 2005-05-20 | 2018-11-09 | Ablynx Nv | Improved nanobodies tm for the treatment of aggregation-mediated disorders |
| JP2009519011A (en) | 2005-12-01 | 2009-05-14 | ドマンティス リミテッド | Non-competitive domain antibody format that binds to interleukin 1 receptor type 1 |
| AU2006321367B2 (en) | 2005-12-01 | 2011-11-03 | Domantis Limited | Competitive domain antibody formats that bind Interleukin 1 Receptor type 1 |
| FR2894741B1 (en) | 2005-12-08 | 2009-12-04 | Centre Nat Etd Spatiales | SATELLITE RECEPTION CHAIN |
| EP1976991A1 (en) | 2006-01-24 | 2008-10-08 | Domantis Limited | Fusion proteins that contain natural junctions |
| US8629244B2 (en) | 2006-08-18 | 2014-01-14 | Ablynx N.V. | Interleukin-6 receptor binding polypeptides |
| WO2008028977A2 (en) * | 2006-09-08 | 2008-03-13 | Ablynx N.V. | Serum albumin binding proteins with long half-lives |
| WO2009138519A1 (en) | 2008-05-16 | 2009-11-19 | Ablynx Nv | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRs AND COMPOUNDS COMPRISING THE SAME |
| KR20120125601A (en) | 2007-05-24 | 2012-11-16 | 아블린쓰 엔.브이. | Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders |
| EP2650311A3 (en) | 2007-11-27 | 2014-06-04 | Ablynx N.V. | Amino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same |
| DE102008023620A1 (en) | 2008-05-15 | 2009-11-19 | Mettler-Toledo (Albstadt) Gmbh | Function unit with an invocable function and method for calling it |
| SI2334705T1 (en) | 2008-09-26 | 2017-05-31 | Ucb Biopharma Sprl | Biological products |
| WO2010130832A2 (en) | 2009-05-15 | 2010-11-18 | Ablynx N.V. | Amino acid sequences directed against dickkopf-1 and polypeptides comprising the same for the treatment of diseases and disorders associated with bone loss and/or osteolytic lesions |
| CA2768462A1 (en) | 2009-07-16 | 2011-01-20 | Glaxo Group Ltd. | Improved anti-serum albumin binding single variable domains |
| CN102666586A (en) | 2009-09-30 | 2012-09-12 | 葛兰素集团有限公司 | Drug fusions and conjugates with extended half life |
| WO2012020143A1 (en) | 2010-08-13 | 2012-02-16 | Glaxo Group Limited | Improved anti-serum albumin binding variants |
| CA2808683A1 (en) | 2010-08-20 | 2012-02-23 | Glaxosmithkline Intellectual Property Development Limited | Improved anti-serum albumin binding variants |
| US11644471B2 (en) * | 2010-09-30 | 2023-05-09 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| EP2621953B1 (en) * | 2010-09-30 | 2017-04-05 | Ablynx N.V. | Biological materials related to c-met |
| LT2723771T (en) * | 2011-06-23 | 2019-12-10 | Ablynx Nv | Serum albumin binding proteins |
| IL293155A (en) * | 2011-06-23 | 2022-07-01 | Ablynx Nv | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| US20150344568A1 (en) * | 2011-06-23 | 2015-12-03 | Ablynx N.V. | Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains |
| WO2012174741A1 (en) | 2011-06-24 | 2012-12-27 | Google Inc. | Determining cross-language query suggestion based on query translations |
| PE20141522A1 (en) | 2011-08-17 | 2014-11-17 | Glaxo Group Ltd | PROTEINS AND MODIFIED PEPTIDES |
| US20130129727A1 (en) * | 2011-11-17 | 2013-05-23 | Nanjingjinsirui Science & Technology Biology Corporation | Methods and systems for increasing protein stability |
| WO2014037419A1 (en) * | 2012-09-04 | 2014-03-13 | Vib Vzw | Immunoglobulin single variable domains directed against cd74 and uses derived thereof |
| US20140186365A1 (en) | 2013-01-03 | 2014-07-03 | Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center | Antibodies that specifically bind to serum albumin without interfering with albumin's capability to interact with the fcrn |
| WO2014111550A1 (en) | 2013-01-17 | 2014-07-24 | Glaxosmithkline Intellectual Property Development Limited | Modified anti-serum albumin binding proteins |
| SG10201805288QA (en) | 2014-05-16 | 2018-07-30 | Ablynx Nv | Improved immunoglobulin variable domains |
| CN107531777A (en) | 2015-01-21 | 2018-01-02 | 英伊布里克斯有限合伙公司 | Non-immunogenic single domain antibody |
| LT3294768T (en) | 2015-05-13 | 2019-11-11 | Ablynx Nv | T cell recruiting polypeptides based on tcr alpha/beta reactivity |
| CN109310751A (en) | 2015-10-22 | 2019-02-05 | 摩登纳特斯有限公司 | Wide spectrum influenza virus vaccine |
| CA3006398A1 (en) | 2015-11-27 | 2017-06-01 | Ablynx Nv | Polypeptides inhibiting cd40l |
| EP3448987A4 (en) * | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| US11414480B2 (en) | 2016-12-07 | 2022-08-16 | Ablynx N.V. | Serum albumin binding immunoglobulin single variable domains |
| SG11201906264YA (en) | 2017-01-17 | 2019-08-27 | Ablynx Nv | Improved serum albumin binders |
-
2018
- 2018-01-17 KR KR1020237040677A patent/KR20230165374A/en active Application Filing
- 2018-01-17 JP JP2019538383A patent/JP7300385B2/en active Active
- 2018-01-17 KR KR1020197024114A patent/KR102653724B1/en active IP Right Grant
- 2018-01-17 EP EP18703213.1A patent/EP3571224A1/en active Pending
- 2018-01-17 AU AU2018209150A patent/AU2018209150A1/en active Pending
- 2018-01-17 BR BR112019014600-8A patent/BR112019014600A2/en unknown
- 2018-01-17 CN CN202311114345.5A patent/CN117327175A/en active Pending
- 2018-01-17 IL IL305912A patent/IL305912A/en unknown
- 2018-01-17 MX MX2019008536A patent/MX2019008536A/en unknown
- 2018-01-17 SG SG10202108973SA patent/SG10202108973SA/en unknown
- 2018-01-17 US US16/477,927 patent/US11897944B2/en active Active
- 2018-01-17 CA CA3050574A patent/CA3050574A1/en active Pending
- 2018-01-17 SG SG11201906341XA patent/SG11201906341XA/en unknown
- 2018-01-17 CN CN201880015687.2A patent/CN110461870B/en active Active
- 2018-01-17 WO PCT/EP2018/051082 patent/WO2018134234A1/en unknown
-
2019
- 2019-07-07 IL IL267897A patent/IL267897A/en unknown
-
2022
- 2022-10-20 JP JP2022168448A patent/JP2023002700A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20190104609A (en) | 2019-09-10 |
| US20190367598A1 (en) | 2019-12-05 |
| JP2020506898A (en) | 2020-03-05 |
| KR102653724B1 (en) | 2024-04-02 |
| RU2019125949A3 (en) | 2021-03-09 |
| MX2019008536A (en) | 2019-09-10 |
| WO2018134234A1 (en) | 2018-07-26 |
| AU2018209150A1 (en) | 2019-07-25 |
| JP2023002700A (en) | 2023-01-10 |
| CA3050574A1 (en) | 2018-07-26 |
| IL305912A (en) | 2023-11-01 |
| US11897944B2 (en) | 2024-02-13 |
| EP3571224A1 (en) | 2019-11-27 |
| KR20230165374A (en) | 2023-12-05 |
| CN110461870B (en) | 2023-09-29 |
| BR112019014600A2 (en) | 2020-02-18 |
| JP7300385B2 (en) | 2023-06-29 |
| SG11201906341XA (en) | 2019-08-27 |
| IL267897A (en) | 2019-09-26 |
| RU2019125949A (en) | 2021-02-19 |
| CN117327175A (en) | 2024-01-02 |
| CN110461870A (en) | 2019-11-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL267894A (en) | Improved serum albumin binders | |
| IL267897A (en) | Improved serum albumin binders | |
| IL263102A (en) | Single domain serum albumin binding protein | |
| ZA201804317B (en) | Altered april binding antibodies | |
| HK1251480A1 (en) | Cd3 binding polypeptides | |
| ZA201804601B (en) | Psma binding antibody and uses thereof | |
| FI4012087T3 (en) | Binder system | |
| RS59233B1 (en) | Heat-sealable binder | |
| GB201610063D0 (en) | Binders | |
| ZA201906821B (en) | Anti-jagged1 antigen binding proteins | |
| IL267318A (en) | Binding assay | |
| ZA201901862B (en) | Modified factor h binding protein | |
| GB201808868D0 (en) | Binder | |
| IL269477A (en) | Il-1r-i binding polypeptide | |
| EP3750824C0 (en) | Binder | |
| GB201614627D0 (en) | Antigen binding proteins | |
| GB201615588D0 (en) | TSLP Binding Proteins | |
| GB201715149D0 (en) | IL-ß binding antibody | |
| HRP20181700T1 (en) | Binding folder | |
| GB201802995D0 (en) | File serving | |
| ZA201707980B (en) | Binding folder | |
| GB201618186D0 (en) | Binding members | |
| HUP1600176A2 (en) | Disc-type binder |